End-of-day quote
Shenzhen S.E.
23:00:00 14/05/2024 BST
|
5-day change
|
1st Jan Change
|
11.74
CNY
|
+0.60%
|
|
-0.17%
|
-10.31%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,564
|
6,728
|
8,893
|
7,059
|
6,524
|
5,609
|
-
|
-
|
Enterprise Value (EV)
1 |
4,564
|
6,728
|
8,893
|
7,059
|
6,524
|
5,609
|
5,609
|
5,609
|
P/E ratio
|
64.6
x
|
87.7
x
|
94.6
x
|
68.7
x
|
37.5
x
|
22.2
x
|
16.5
x
|
12.9
x
|
Yield
|
-
|
0.44%
|
0.28%
|
-
|
-
|
1.11%
|
1.53%
|
1.96%
|
Capitalization / Revenue
|
-
|
12.2
x
|
13.6
x
|
-
|
-
|
3.98
x
|
3.05
x
|
2.48
x
|
EV / Revenue
|
-
|
12.2
x
|
13.6
x
|
-
|
-
|
3.98
x
|
3.05
x
|
2.48
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
11.6
x
|
9.06
x
|
7.28
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
6.73
x
|
8.3
x
|
-
|
-
|
4.77
x
|
3.86
x
|
3.11
x
|
Nbr of stocks (in thousands)
|
491,785
|
491,785
|
495,713
|
500,623
|
498,389
|
477,755
|
-
|
-
|
Reference price
2 |
9.280
|
13.68
|
17.94
|
14.10
|
13.09
|
11.74
|
11.74
|
11.74
|
Announcement Date
|
28/02/20
|
28/04/21
|
27/03/22
|
16/02/23
|
29/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
552.6
|
656.3
|
-
|
-
|
1,409
|
1,839
|
2,261
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
482
|
619
|
770
|
EBIT
1 |
-
|
99.73
|
119.2
|
-
|
-
|
358
|
476
|
610
|
Operating Margin
|
-
|
18.05%
|
18.16%
|
-
|
-
|
25.41%
|
25.88%
|
26.98%
|
Earnings before Tax (EBT)
1 |
-
|
98.44
|
119.4
|
-
|
-
|
358
|
476
|
610
|
Net income
1 |
70.68
|
76.73
|
95.29
|
102.6
|
176.6
|
272
|
362
|
463
|
Net margin
|
-
|
13.89%
|
14.52%
|
-
|
-
|
19.3%
|
19.68%
|
20.48%
|
EPS
2 |
0.1437
|
0.1560
|
0.1896
|
0.2051
|
0.3487
|
0.5300
|
0.7100
|
0.9100
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
0.0600
|
0.0500
|
-
|
-
|
0.1300
|
0.1800
|
0.2300
|
Announcement Date
|
28/02/20
|
28/04/21
|
27/03/22
|
16/02/23
|
29/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
7.88%
|
9.2%
|
-
|
-
|
21.7%
|
23.3%
|
24.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
8.03%
|
9.31%
|
10.5%
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
3,387
|
3,888
|
4,422
|
Book Value Per Share
2 |
-
|
2.030
|
2.160
|
-
|
-
|
2.460
|
3.040
|
3.770
|
Cash Flow per Share
2 |
-
|
0.2900
|
0.2700
|
-
|
-
|
0.9100
|
0.9200
|
1.120
|
Capex
1 |
-
|
155
|
217
|
-
|
-
|
275
|
280
|
296
|
Capex / Sales
|
-
|
27.99%
|
33.01%
|
-
|
-
|
19.52%
|
15.23%
|
13.09%
|
Announcement Date
|
28/02/20
|
28/04/21
|
27/03/22
|
16/02/23
|
29/03/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -10.31% | 777M | | +31.37% | 595B | | -2.60% | 367B | | +20.83% | 334B | | +5.69% | 289B | | +14.83% | 239B | | +9.93% | 211B | | -6.95% | 203B | | +10.77% | 171B | | +0.10% | 163B |
Other Pharmaceuticals
|